CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 421 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03703817
NCT03703817N/ACompleted

TREATMENT SATISFACTION COMPARISON IN RHEUMATOID ARTHRITIS PATIENTS BETWEEN TOFACITINIB CITRATE AND ADALIMUMAB, EACH USED IN RHEUMATOID ARTHRITIS TREATMENT

Pfizer·observational·Posted Oct 12, 2018·Updated Mar 16, 2021

In Brief

An observational study for Rheumatoid Arthritis. Completed, enrolled 421 participants across 23 sites.

Detailed Summary

RA satisfaction OR: This study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2 year in RA treatment of rheumatoid arthritis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
CollaboratorsYonsei University

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 12, 2018
Enrollment StartJul 2, 2018
Primary CompletionMar 12, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.7 years ago